Cash/Burn From SEC Filing For Period: 

Q1 '20

ZGNX

Zogenix

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States.

Cash

$420.2M

Burn Rate

-$25.8M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

FINTEPLA (ZX008)

Dravet syndrome

Quarterly Sales (Approved)

November 6, 2020 (Est)

ZX008

Lennox-Gastaut syndrome

sNDA Submission (Meeting with FDA)

September 2020

MT1621

Thymidine Kinase 2 (TK2)

Phase 2 (Open Label)

TBD

ZX008

Multiple Rare Epilepsies

Phase 2

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

ZGNX Fintepla approved for Dra...

Congrats to ZGNX on FDA approval of Fintepla for Dravet (See our AmpCard https://bit.ly/3evfnLU for published data & more). It will be interesting to see how well it competes with GWPH EPIDOLEX. Will ...

[DD Example] Zogenix: Major Up...

#ZGNX #LGS #Phase3 This is an example of what you can find in our Deeper Diligence channel here. You can access these deeper diligence articles by becoming a free member today, just click "Sign Up" i...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon